SCHEMBL21556098

SCHEMBL21556098

CC1(Oc2ccc(S(=O)(=O)Cl)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
PKM P14618 3/20 0.35
DRD2 P14416 3/20 0.35
LRRK2 Q5S007 3/20 0.34
PTGS1 P23219 2/20 0.33
PTGS2 P35354 2/20 0.33
NPC1 O15118 1/20 0.33
PKLR P30613 1/20 0.33
RAB9A P51151 1/20 0.33
HTT P42858 4/20 0.32
LMNA P02545 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
EEF2K O00418 1/20 0.32
MMP13 P45452 1/20 0.32
POLB P06746 2/20 0.32
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20474625 0.81 ALDH1A1 (0.53) ALDH1A1TDP1PTGS1PTGS2HTT
SCHEMBL29799492 0.78 ESR1 (0.39) DRD2MMP13
SCHEMBL21556045 0.75 ALDH1A1 (0.50) ALDH1A1PTGS1PTGS2HTTTSHR
SCHEMBL21556099 0.74 ALDH1A1 (0.48) ALDH1A1PTGS1PTGS2HTTTSHR
SCHEMBL21556048 0.73 CA12 (0.32) ALDH1A1HSD17B10TDP1TSHRKMT2A
SCHEMBL20474622 0.72 HSPB1 (0.47) ALDH1A1HSD17B10PTGS2NPC1RAB9A
SCHEMBL67837 0.71 PKM (0.67) ALDH1A1HSD17B10TDP1PKMPTGS2
SCHEMBL6108870 0.71 PKM (0.67) ALDH1A1HSD17B10TDP1PKMPTGS2
SCHEMBL9720036 0.71 HTT (0.58) ALDH1A1HSD17B10TDP1PKMNPC1
SCHEMBL433497 0.71 HTT (0.58) ALDH1A1HSD17B10TDP1PKMNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472386-B2 Bile acid derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472386-B2 Bile acid derivatives as FXR agonists and methods of use thereof NR1H4, GPBAR1, SLC10A1 ALDH1A1 1993/4885HSD17B10 198/4885TDP1 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.